Abs#0608 #ACR23 @RheumNow Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE P2 CARE Study 51% of pts had high IFN1 sign., ass w/ high dsDNA Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4

Abs#595 #ACR23 @RheumNow R Furie on 4 yr TULIP-LTE pts with b/l renal involvement 33% on anifrolumab continued to wk 208 vs PBO 6% Renal improvement at w208 in 9/10 pts, vs no avail PBO data Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement

Translational implication/application of the #APOL1 story : Risk stratification, novel treatments, impact of tissue susceptibility to damage #ACR23 @RheumNow #DuboisLecture #SLE @ashira_md https://t.co/k23vFjeDeG

#ACR23 Please find my preview article on selected #SLE abstracts to be presented at year’s conference - towards Glucocorticoid-Free zone in lupus @RheumNow https://t.co/1kM7LWc64V https://t.co/WK9X7UpsNi

In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s

In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs Further prospective studies req'd? BEL remains an option for non-renal SLE tx. #ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk

Did you know? 👉APOL1 variants are protective against trypanosomiasis. 👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had: ⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ

CV events in women w/ ARDs pregnancies: -2.0% of 19,340 pregnant ARDs Adjusted relative risk: -4 fold in ARD -15 fold in primary APS -6 fold in SLE -SLE + APS 18 fold 25-30% occur in early post partum! Need for continued vigilance after delivery @RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB

CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW

Always great to see UCSD represent at #ACR23! Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events 30% of events occurred postpartum @RheumNow Abs#0722 https://t.co/CqZedfOlBC

#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc

Plenary 1 #ACR23 CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko

Should all of active moms with #SLE receive DVT prophylaxis post partum? High rates of VTE in #ARDs post partum #0722 #ACRbest #ACR23 @RheumNow @ACRheum Likely data driven by #SLE and maybe #RA and not all #autoimmune #rheumatic #disease. Large pop’n data from California https://t.co/sGJa5N6HUj

Plenary talk by Dhital etc al, shows increased risk of acute CV events in pregnant rheumatic, SLE, APS pts, esp if nephritis or APL+. #ACR23 Abstract 0722 https://t.co/pG0PqzVtIU